Compare MEC & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | GHRS |
|---|---|---|
| Founded | 1945 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 885.7M | 947.2M |
| IPO Year | 2019 | 2021 |
| Metric | MEC | GHRS |
|---|---|---|
| Price | $33.90 | $26.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $24.33 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 593.6K | 250.9K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $8.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.10 | $11.32 |
| 52 Week High | $38.76 | $28.96 |
| Indicator | MEC | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 52.08 | 64.96 |
| Support Level | $33.06 | $12.88 |
| Resistance Level | $36.50 | N/A |
| Average True Range (ATR) | 1.89 | 1.71 |
| MACD | -0.40 | 0.48 |
| Stochastic Oscillator | 9.55 | 79.34 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.